The prognosis of patients with primary resistant or relapsed T-ALL remains poor, and development of
targeted drugs are still necessary. Therefore, new targets must be identified. SOX11 is a transcription
factor. Under physiological conditions, SOX11 is absent in the T-cell lineage, however, SOX11 is
upregulated in a subset of T-ALL cases. We aim to unravel the role of SOX11 in T-ALL.